Deucravacitinib for the treatment of moderate-to-severe palmoplantar pustulosis: Results from an early-terminated open-label trial.

Ramessur, R., Fuxench, Z. C. C., Shin, D., Mason, J. B., Mason, A. C., Papadopoulos, M., Wafae, B. G. de O., Noe, M. H., & Gelfand, J. M. (2026). Deucravacitinib for the treatment of moderate-to-severe palmoplantar pustulosis: Results from an early-terminated open-label trial.. JAAD International, 24, 84-86.
Last updated on 04/01/2026
PubMed